FTC Accuses Boehringer Of Subpoena Delay Tactics

Law360, New York (October 27, 2009, 7:45 PM EDT) -- The Federal Trade Commission, investigating a patent settlement between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drug entry, has asked for a court order requiring Boehringer to comply with the terms of a subpoena.

In a petition filed Friday in the U.S. District Court for the District of Columbia, the FTC accuses Boehringer of using a number of tactics to delay the investigation, such as inappropriately redacting documents and failing to conduct a careful and thorough search.

“Nearly nine...
To view the full article, register now.